Trial record 4 of 12 for:
Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma
This study has been completed.
Information provided by (Responsible Party):
First received: June 6, 2002
Last updated: September 6, 2012
Last verified: September 2012
The primary goal of this study is to determine if people with metastatic melanoma who receive Heat Shock Protein-Peptide Complex - 96 (HSPPC-96 or Oncophage) after surgery live longer than people who may or may not have surgery but who receive conventional chemotherapy including IL-2/DTIC. A second goal is to determine the safety and frequency of side effects in subjects who receive therapy with HSPPC-96.
Drug: HSPPC-96 or Oncophage
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
||A Phase III Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus Physician's Choice Including Interleukin-2 and/or Dacarbazine/Temozolomide-based Therapy and/or Complete Tumor Resection in Stage IV Melanoma
| Estimated Enrollment:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||December 2005 (Final data collection date for primary outcome measure)
- To determine whether subjects with stage IV melanoma randomized to HSPPC-96 have longer survival than subjects randomized to physician's choice including interleukin-2 and/or dacarbazine/temozolomide and/or complete tumor resection.
- To determine frequency of adverse events in subjects randomized to HSPPC-96.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
(The following assessments must be obtained within three weeks prior to randomization into the study)
- Medical history and physical examination (including EGOG score, evidence of immunosuppression);
- CT/MRI of the chest, abdomen and pelvis;
- Clinical examination;
- CT/MRI of the brain;
- Complete Blood Count with differential including platelets;
- Electrolytes (Na, Cl, K, HCO3, Ca, Mg, PO4);
- Renal function tests (BUN and creatinine);
- Liver function tests (bilirubin, AST, ALT);
- Serum pregnancy test for all women of childbearing potential.
- Stage IV Melanoma (AJCC);
- No prior therapy for stage IV melanoma;
- No prior therapy with interleukin-2 and/or dacarbazine/temozolomide within the past 12 months prior to study entry;
- Candidate for surgical resection of some/all sites of melanoma and expected to obtain greater tan or equal to 7 grams of viable cancer tissue (in aggregate), which is equivalent to a greater than or equal to 2 cm lesion on CT/MRI or clinical examination;
- No brain metastases;
- ECOG score 0 or 1;
- Adequate cardiac function;
- Adequate hematopoietic, liver and renal function;
- Female subjects of child-bearing potential must agree to use contraception during the study
- Signed written informed consent.
- Mucosal or ocular melanomas;
- Other malignancies treated within the last five years, except in situ cervix carcinoma or non-melanoma skin cancer;
- Primary or secondary immunodeficiency, in the opinion of the investigator (including immunosuppressive disease, or use of systemic corticosteroids or other immunosuppressive medications);
- Prior splenectomy;
- Uncontrolled infection or other serious medical illnesses;
- Women who are pregnant or breast-feeding;
- Subjects participating in any other studies requiring administration of an investigational drug/biologic agent.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00039000
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||June 6, 2002
||September 6, 2012
||United States: Food and Drug Administration
Keywords provided by Agenus, Inc.:
Immunotherapy, Cancer, Melanoma, Skin Cancer, tumor
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on April 16, 2015
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Nevi and Melanomas